Mechanism of Action (MOA) Analysis
for Rare Cancer (Pre-Print)

We recently conducted a Mechanism of Action (MOA) analysis using our machine learning-enabled Elion platform to predict MOAs of novel agents effective against Lymphangioleiomyomatosis (LAM), a rare cancer. The MOA process identified histone deacetylation as a crucial mechanism in novel hits reducing cancer cell invasion, as confirmed by subsequent in vitro analysis.

A publication of that research, led by Dr. William Stanford of the The Ottawa Hospital Research Institute, is undergoing peer review, and is viewable online as a pre-print on bioRxiv. To view more, click here.